Close this search box.

Neurimmune expands drug discovery collaboration with Ono Pharmaceutical

Swiss Neurimmune AG has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. covering antibody drug targeting neurodegenerative diseases

The collaboration complements an agreement from November 2017, designed to identify and develop human antibodies using Neurimmune’s RTMTM technology platform. Under the new collaboration, the companies aim to generate and validate human-derived monoclonal antibodies against Ono’s newly selected drug targets. Ono will obtain exclusive rights for worldwide development and commercialization of antibody products resulting from the collaboration. Ono will pay to Neurimmune an upfront payment, research fees, success-based milestones on the research and development progress, as well as royalties on product sales.